U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438860) titled 'Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG' on Feb. 03.
Brief Summary: Participants in this research study are people who are likely to have, or have been diagnosed with a brain tumor, for which surgical removal (or "resection") is the standard of care treatment. The purpose of this study is to see whether a drug called SBK2-ICG can be used to locate the true outline or "edges" of the tumor. If the tumor outline could be accurately identified at the time of surgery, the fullest extent of tumor could be removed while sparing the normal brain tissue.
Participants will receive SBK2-ICG about an hour bef...